摘要
HCV感染在肾功能不全(RD)患者中较常见,尤其是在终末期肾病进行血液透析(HD)的患者中,感染率明显高于普通人群,肝脏疾病的发生率及病死率升高。直接抗病毒药物在慢性丙型肝炎的治疗中取得了超过90%的持续病毒学应答和较少的不良事件。在合并RD和HD患者中推荐应用grazoprevir/elbasvir、paritaprevir/ritonavir+ombitasvir+dasabuvir、glecaprevir/pibrentasvir或daclartasvir+asunaprevir等治疗方案,不建议推荐以sofosbuvir为基础的治疗方案。
The incidence of hepatitis C virus infection is commonly seen in patients with renal dysfunction（RD）,especially those with end-stage renal disease on hemodialysis（HD）,among whom the incidence and mortality of liver diseases increase.The development of direct-acting antiviral agents has revolutionized the therapy for chronic hepatitis C（CHC） with a sustained virologic response rate of 90% and a low rate of adverse events.Grazoprevir/elbasvir,paritaprevir/ritonavir ＋ ombitasvir ＋ dasabuvir,glecaprevir/pibrentasvir,or daclatasvir ＋ asunaprevir regimen is recommended in CHC patients with RD and HD,while the sofosbuvir-based regimen is not recommended.
出处
《临床肝胆病杂志》
CAS
北大核心
2018年第2期251-254,共4页
Journal of Clinical Hepatology
基金
十二五重大专项(2012ZX10002003-004-003)
国家自然科学基金(81373056)
关键词
肝炎
丙型
慢性
肾功能不全
血液透析滤过
抗病毒药
hepatitis C chronic
renal insufficiency
hemodiafiltration
antiviral agents
